

Association Between Congenital or Acquired Physical Disability Conditions that Affect Central Nervous System and Risk of Alzheimer's Disease and Related Dementia

ICPSR

September 21, 2020

Elham Mahmoudi, PhD and Neil Kamdar, MA
Department of Family Medicine and Institute for Healthcare Policy and Innovation
University of Michigan

mahmoudi@med.umich.edu and neilseal@med.umich.edu

Acknowledgement

Co-Authors:

Paul Lin, MS

Mark Peterson, PhD

Michelle Meade, PhD

Denise Tate, PhD

Disclosure

No conflicts of interest to disclose

Funding: The National Institute on Disability,
Independent Living, and Rehabilitation Research
(NIDILRR #90RTHF0001-01-00)

Overview

- Background
- Study's Aims
- Data and Methods
- Results
- Policy Implications
- Limitations
- Future Work
- Questions/Answers

Background

Cerebral Palsy and Spina Bifida

- Cerebral palsy (CP) and spina bifida (SB) are congenital diseases known to cause an array of permanent movement disorders.
- Incidence rates: 2-2.5 per 1,000 births for CP and 1 in 3,000 births for SB.
- Life expectancy for adults with CP/SB has substantially increased over the last two decades.




Multiple Sclerosis (MS)



- Multiple Sclerosis (MS) is a chronic, inflammatory disease of the central nervous system, impacting the protective myelin sheath of nerve fibers in the brain and spinal cord.
- Typically diagnosed between the ages of 20 and 40.
- Neuroinflammation is a prominent feature of MS pathology

Traumatic Spinal Cord Injury (TSCI)

- TSCI is mostly caused by motor vehicle accidents, falls, or act of violence.
- Due to neuronal damage, TSCI may exacerbate certain biological mechanisms that elevate the risk for ADRD.



What do we know about the association between these conditions and ADRD?

- For CP/SB, research has been mainly focused on pediatric issues.
- Although there are a lot of similarities between MS and ADRD pathology, results from clinical trials were mixed and sample sizes were small.
- For TSCI, research has been mainly focused on physical rather than cognitive function.

What do we know about the association between these conditions and ADRD?

- Prevalence and incidence rate of cardiometabolic, psychological, and musculoskeletal conditions are substantially higher among adults with CP/SB, MS, and TSCI compared to their adult counterparts without disability.
- Higher prevalence of cardiometabolic, psychological, and musculoskeletal conditions have been linked with ADRD.

Aims

Objective

- To examine time to diagnosis of and adjusted hazard for ADRD, comparing adults with and without CP/SB, MS, and TSCI. comparing the risk with a matched-cohort of adults without any disability

Data & Methods

Dataset

- Commercial claims Data from OptumInsight
- Study period:2007-2016
- Patient population: Adults aged 45+ years at the time of insurance enrollment with diagnosis of CP/SB, MS, or TSCI at any point during the study period

Patient Population

Disability Condition	Unmatched		Matched	
	Case	Control	Case	Control
CP/SB	7,875	1,119,131	7,726	7,726
MS	6,151	916,143	6,025	6,025
TSCI	7,019	916,516	6,083	6,083

Study Design (1)


- Outcome of Interest:
 - Incident ADRD within a 4-year period
- Independent Variables:
 - Demographics: age, sex, race/ethnicity, U.S. Census Divisions
 - Health: diagnosis of cardiometabolic, psychologic, and musculoskeletal conditions during the 1-year look back period
 - Socioeconomic: Net worth and educational attainment

Study Design (2)

Survival models were used to quantify unadjusted, fully adjusted, and propensity-matched unadjusted and adjusted hazard ratios for incident ADRD.

Results


Incident ADRD among Adults with CP/SB




Kaplan-Meier Curves for Adults with CP/SB

(A)

Unmatched




(B) Matched



Hazard Ratios of CP/SB for ADRD


Age	Unmatched Cohort		Matched Cohort	
	Unadjusted	Adjusted	Unadjusted	Adjusted
45-64 years of age	7.84 (6.45, 9.52) ***	5.91 (4.87, 7.18) ***	3.63 (2.36, 5.58) ***	3.35 (2.18, 5.14) ***
65+ years of age	2.49 (2.22, 2.79) ***	1.88 (1.68, 2.11) ***	1.79 (1.47, 2.17) ***	1.68 (1.38, 2.03) ***

Incident ADRD among Adults with MS




Kaplan-Meier Curves for Adults with MS

A. Unmatched




B. Matched



Hazard Ratios of MS for ADRD

Age	Unmatched Cohort		Matched Cohort	
	Unadjusted	Adjusted	Unadjusted	Adjusted
45-64 years of age	5.20 (4.16, 6.50) ***	4.25 (3.40, 5.32) ***	4.71 (2.74, 8.08) ***	4.49 (2.62, 7.69) ***
65+ years of age	1.68 (1.47, 1.91) ***	1.39 (1.22, 1.58) ***	1.33 (1.09, 1.62) ***	1.26 (1.04, 1.54) ***



Incident ADRD among Adults with TSCI



Kaplan-Meier Curves for Adults with TSCI

A. Unmatched

B. Matched

Product-Limit Survival Estimates
With 95% Hall-Wellner Bands**Product-Limit Survival Estimates**
With 95% Hall-Wellner Bands

Hazard Ratios of CP/SB for ADRD

	Unmatched Cohort		Matched Cohort	
	Unadjusted	Adjusted	Unadjusted	Adjusted
45-64 years of age	4.08 (2.93, 5.67) ***	3.19 (2.30, 4.44) ***	1.99 (1.09, 3.62) ***	1.93 (1.06, 3.51) ***
65+ years of age	2.51 (2.34, 2.70) ***	1.90 (1.77, 2.04) ***	1.79 (1.56, 2.04) ***	1.77 (1.55, 2.02) ***

Conclusions

- Both middle-aged and older adults with CP/SB, MS, and TSCI had higher incident ADRD compared to those without disabilities.
- Fully adjusted survival models indicated that adults with aforementioned disabilities had a greater hazard for ADRD.

Limitations

- Lack of more granular socioeconomic data
- Lack of any measure for cognitive function
- Underdiagnosis of ADRD
- Hard to define index diagnosis of comorbid conditions
- Results are not representative of the U.S. population
- Potential selection bias – inclusion of privately insured with higher income and education

Policy Implications

- Although there is no cure for ADRD, research shows that diet, lifestyle, routine exercise, and some therapeutic may slow down the onset of ADRD and/or help preserve level of cognitive function.
- Improved clinical screening and early interventions aiming to preserve cognitive function are of paramount importance for this patient cohort.

Questions and Answers

Thank you!

mahmoudi@med.umich.edu

neilseal@med.umich.edu